Research programme: cancer therapeutics - BeiGene

Drug Profile

Research programme: cancer therapeutics - BeiGene

Alternative Names: BGB-108; BGB-A425; Brodomain containing protein 4 inhibitors - BeiGene; EGFR T790 mutation inhibitors - BeiGene; iOnc monoclonal antibody - BeiGene; iONC small molecule therapeutic - BeiGene; KRAS protein inhibitors - BeiGene; PD-1 monoclonal antibody - BeiGene; PD-L1 monoclonal antibody - BeiGene; Tim-3 antibody

Latest Information Update: 12 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BeiGene
  • Class Monoclonal antibodies; Small molecules
  • Mechanism of Action BRD4-protein-inhibitors; CD274 antigen modulators; Epidermal growth factor inhibitors; HAVCR2 protein modulators; Immunomodulators; KRAS protein inhibitors; PDCD 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jan 2018 BeiGene in-licenses H2L2 transgenic mouse platform from Harbour BioMed
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 14 Nov 2014 Preclinical trials in Cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top